FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
MediumReport
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics [Yahoo! Finance]
MediumReport
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics [Yahoo! Finance]
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
MediumReport
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: